Skip to main content

Advertisement

Log in

Pregabalin abuse and dependence in Germany: results from a database query

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Pregabalin (PRG) is approved for the treatment of neuropathic pain, partial seizures and generalised anxiety disorder in many countries and currently under study for other indications. Supported by case reports and the results of a limited number of studies there is an ongoing debate on the potential of PRG to cause addictive behaviours. However, currently available evidence on this issue is sparse, and any definitive assessment of PRG’s potential for abuse and dependence is not yet in sight. The aim of our study was to identify the number of cases of PRG abuse or dependence reported to the database of a German medical regulatory body and to obtain insights into further usage-specific parameters.

Methods

We conducted a query of the entire database of the German Federal Institute for Drugs and Medical Devices (BfArM) regarding reports of PRG abuse or dependence and analysed these cases on the basis of several parameters.

Results

A total of 55 reports of PRG abuse or dependence were identified (mean age 36 years, 64 % of reports involved males). The first reports were submitted to BfArM in 2008, and the reporting frequency has increased up to the present. Mean daily PRG dosage was 1424 mg. Current or previous polytoxicomania was present in 40 and 42 % of cases, respectively. Psychiatric diagnoses other than substance-related disorders were reported in 13 (24 %) cases. In about one-third of the patients withdrawal syndromes subsequent to discontinuation of PRG were reported.

Conclusions

Cases of PRG abuse or dependence have been reported to the BfArM since 2008, with a marked increase of such reports in subsequent years. Male sex and a history of polytoxicomania may be possible risk factors for the development of addictive behaviours related to PRG.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dworkin R, Kirkpatrick P (2005) Pregabalin. Nat Rev Drug Discov 4:455–456

    Article  PubMed  CAS  Google Scholar 

  2. Federal Drug Administration (FDA) (2008) Living with fibromyalgia, drugs approved to manage pain. FDA, Washington D.C.

  3. Wensel T, Powe K, Cates M (2012) Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother 46:424–429

    Article  PubMed  Google Scholar 

  4. Richards B, Whittle S, van der Heijde D, Buchbinder R (2012) Efficacy and safety of neuromodulators in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl 90:28–33

    Article  PubMed  CAS  Google Scholar 

  5. Aboumarzouk O, Nelson R (2012) Pregabalin for chronic prostatitis. Cochrane Database Syst Rev 8:CD009063

    PubMed  Google Scholar 

  6. Aurora R, Kristo D, Bista S, Rowley J, Zak R, Casey K, Lamm C, Tracy S, Rosenberg R (2012) The treatment of restless legs syndrome and periodic limb movement disorder in adults—an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine clinical practice guideline. Sleep 35:1039–1062

    PubMed  Google Scholar 

  7. Balaban F, Yağar S, Özgök A, Koç M, Güllapoğlu H (2012) A randomized, placebo-controlled study of pregabalin for postoperative pain intensity after laparoscopic cholecystectomy. J Clin Anesth 24:175–178

    Article  PubMed  CAS  Google Scholar 

  8. Kapfhammer H (2012) Psychopharmacological treatment in patients with somatoform disorders and functional body syndromes. Nervenarzt 83:1128–1141

    Article  PubMed  CAS  Google Scholar 

  9. Strawn J, Dowling B, Geracioti TJ (2008) Pregabalin treatment of posttraumatic stress disorder. J Clin Psychopharmacol 28:596–597

    Article  PubMed  Google Scholar 

  10. Schönfeldt-Lecuona C, Wolf R, Osterfeld N, Vasic N, Connemann B, Schmid M, Freudenmann R (2008) Pregabalin in the treatment of schizophrenic anxiety. Pharmacopsychiatry 41:1–2

    Article  Google Scholar 

  11. Oulis P, Konstantakopoulos G, Kouzoupis A, Masdrakis V, Karakatsanis N, Karapoulios E, Kontoangelos K, Papadimitriou G (2008) Pregabalin in the discontinuation of long-term benzodiazepines’ use. Hum Psychopharmacol 23:337–340

    Article  PubMed  CAS  Google Scholar 

  12. Biermann T, Bleich S, Kornhuber J, Hillemacher T (2007) Pregabalin in benzodiazepine withdrawal. Pharmacopsychiatry 40:292–293

    Article  PubMed  CAS  Google Scholar 

  13. Martinotti D, Di Nicola M, Tedeschi D, Mazza M, Janiri L, Bria P (2008) Efficacy and safety of pregabalin in alcohol dependence. Adv Ther 25:608–618

    Article  PubMed  CAS  Google Scholar 

  14. Oulis P, Konstantakopoulos G (2012) Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opin Investig Drugs 21:1019–1029

    Article  PubMed  CAS  Google Scholar 

  15. Toth C (2012) Drug safety evaluation of pregabalin. Expert Opin Drug Saf 11:487–502

    Article  PubMed  CAS  Google Scholar 

  16. Drug Enforcement Administration, Department of Justice (2005) Schedules of controlled substances: placement of pregabalin into Schedule V. Fed Regist 70(144):43633–43635

    Google Scholar 

  17. Chalabianloo F, Schjøtt J (2009) Pregabalin and its potential for abuse. Tidsskr Nor Laegeforen 129:186–187

    Article  PubMed  Google Scholar 

  18. Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, Mann K (2010) Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry 167:869

    Article  PubMed  Google Scholar 

  19. Skopp G, Zimmer G (2012) Pregabalin—a drug with abuse potential? Arch Kriminol 229:44–54

    PubMed  Google Scholar 

  20. Filipetto F, Zipp C, Coren J (2010) Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc 110:605–607

    PubMed  Google Scholar 

  21. Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P (2010) A signal for an abuse liability for pregabalin–results from the Swedish spontaneous drug reaction reporting system. Eur J Clin Psychopharmacol 66:947–953

    Article  Google Scholar 

  22. Caster O, Edwards I, Norén G, Lindquist M (2011) Earlier discovery of pregabalin’s dependence potential might have been possible. Eur J Clin Pharmacol 67:319–320

    Article  PubMed  Google Scholar 

  23. Schifano F, D’Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, Di Melchiorre G, Di Furia L, Farré M, Flesland L, Mannonen M, Majava A, Pagani S, Peltoniemi T, Siemann H, Skutle A, Torrens M, Pezzolesi C, van der Kreeft P, Scherbaum N (2011) Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom 80:118–122

    Article  PubMed  Google Scholar 

  24. Landmark C, Fossmark H, Larsson P, Rytter E, Johannessen S (2011) The prescription registry and abuse of pregabalin. Tidsskr Nor Laegeforen 131:223

    Article  PubMed  Google Scholar 

  25. [No authors listed]. Gabapentin and pregabalin: abuse and addiction (2012) Prescrire Int 21:152–154

  26. Pfizer Inc. (2011). Lyrica (pregablin) capsules (prescribing information). Revised 06/2011. Pfizer, Inc, New York

  27. Schwabe U, Paffrath D (2010) Arzneiverordnungs report 2010. Springer, Berlin Heidelberg New York

  28. Martinotti G (2012) Pregabalin in clinical psychiatry and addiction: pros and cons. Expert Opin Investig Drugs 21:1243–1245

    Article  PubMed  CAS  Google Scholar 

  29. Terracciano A, Löckenhoff C, Crum R, Bienvenu O, Costa P (2008) Five-factor model personality profiles of drug users. BMC Psychiatry 8:22

    Article  PubMed  Google Scholar 

  30. Sills G (2006) The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 6:108–113

    Article  PubMed  CAS  Google Scholar 

  31. Chesler E, Ritchie J, Kokayeff A, Lariviere W, Wilson S, Mogil J (2003) Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. Pain 106:325–335

    Article  PubMed  CAS  Google Scholar 

  32. Martin D, McClelland D, Herd M, Sutton K, Hall M, Lee K, Pinnock R, Scott R (2002) Gabapentin-mediated inhibition of voltage-activated Ca2+ channel currents in cultured sensory neurons is dependent on culture conditions and channel subunit expression. Neuropsychopharmacology 42:353–366

    CAS  Google Scholar 

  33. Rose M, Kam P (2002) Gabapentin: pharmacology and its use in pain management. Anaesthesia 57:451–462

    Article  PubMed  CAS  Google Scholar 

  34. Lanneau C, Green A, Hirst W, Wise A, Brown J, Donnier E, Charles K, Wood M, Davies C, Pangalos M (2001) Gabapentin is not a GABAB receptor agonist. Neuropsychopharmacology 41:965–975

    CAS  Google Scholar 

  35. McClelland D, Evans R, Barkworth L, Martin D, Scott R (2004) A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultures DRG neurons from neonatal rats. BMC Pharmacol 4:14

    Article  PubMed  Google Scholar 

  36. Bian F, Li Z, Offord J, Davis M, McCormick J, Taylor C (2006) Calcium channel α(2)-δ type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autocardiographic study in α(2)-δ type 1 genetically modified mice. Brain Res 1:1–6

    Google Scholar 

  37. Arikkath J, Campbell K (2003) Auxiliary subunits: essential components of the voltage-gated calcium channel complex. Curr Opin Neurobiol 13:298–307

    Article  PubMed  CAS  Google Scholar 

  38. Gazulla J, Tintore M (2007) The P/Q-type voltage-dependent calcium channels as pharmacological target in spinocerebellar ataxia type 6: Gabapentin and pregabalin may be of therapeutic benefit. Med Hypotheses 68:131–136

    Article  PubMed  CAS  Google Scholar 

  39. Field M, Cox P, Stott E, Melrose H, Offord J, Su T, Bramwell S, Corradini L, England S, Winks J, Kinloch R, Hendrich J, Dolphin A, Webb T, Williams D (2006) Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA 103:17537–17542

    Article  PubMed  CAS  Google Scholar 

  40. Gee N, Brown J, Dissanayake V, Offord J, Thurlow R, Woodruff G (1996) The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2-δ subunit of a calcium channel. J Biol Chem 271:5768–5776

    Article  PubMed  CAS  Google Scholar 

  41. Taylor C (2004) The biology and pharmacology of calcium channel α2-δ proteins. CNS Drug Rev 10:183–188

    Article  PubMed  Google Scholar 

  42. Jones D, Sorkin L (1998) Systematic gabapentin and S(+)-3-isobutyl-y-aminobutyric acid block secondary hyperalgesia. Brain Res 810:93–99

    Article  PubMed  CAS  Google Scholar 

  43. Luo Z, Chaplan S, Higuera E, Sorkin L, Staudermann K, Williams M, Yaksh T (2001) Upregulation of the dorsal root ganglion α2-δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 21:1868–1875

    PubMed  CAS  Google Scholar 

  44. Fink K, Dooley D, Meder D, Suman-Chauhan N, Duffy S, Clusmann H, Göthert M (2002) Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42:229–236

    Article  PubMed  CAS  Google Scholar 

  45. Dooley D, Donovan C, Pugsley T (2000) Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 295:1086–1093

    PubMed  CAS  Google Scholar 

  46. Maneuf Y, Hughes J, McKnight A (2001) Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudal trigeminal nucleus slices. Pain 93:191–196

    Article  PubMed  CAS  Google Scholar 

  47. Cunningham M, Woodhall G, Thompson S, Dooley D, Jones R (2004) Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 20:1566–1576

    Article  PubMed  Google Scholar 

  48. Fehrenbacher J, Taylor C, Vasko M (2003) Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105:133–141

    Article  PubMed  CAS  Google Scholar 

  49. Li C, Zhang X, Matthews E, Li K, Kurwa A, Boroujerdi A, Gross J, Gold M, Dickenson A, Feng G, Luo Z (2006) Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. Pain 206:20–34

    Article  Google Scholar 

  50. Chizh B, Gohring M, Troster A, Quartey G, Schmelz M, Koppert W (2007) Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers. Br J Anaesth 98:246–254

    Article  PubMed  CAS  Google Scholar 

  51. Chen S, Xu Z, Pan H (2001) Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats. Anesthesiology 95:1473–1479

    Article  PubMed  CAS  Google Scholar 

  52. Ashton C (2005) Benzodiazepine dependence. In: Haddad P, Dursun D, Deakin B (eds) Adverse syndromes and psychiatric drugs: a clinical guide. Oxford University Press, Oxford, pp 239–260

  53. Lader M (2011) Benzodiazepines revisited—will we ever learn? Addiction 106:2086–2109

    Article  PubMed  Google Scholar 

  54. Stewart B, Kugler A, Thompson P, Bockbrader H (1993) A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 10:276–281

    Article  PubMed  CAS  Google Scholar 

  55. Ben-Menachem E (2004) Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45[Suppl 6]:13–18

    Article  PubMed  CAS  Google Scholar 

  56. Bockbrader H, Radulovic L, Posvar E, Strand J, Alvey C, Busch J, Randinitis E, Corrigan B, Haig G, Boyd R, Wesche D (2010) Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 50:941–950

    Article  PubMed  CAS  Google Scholar 

  57. Tassone D, Boyce E, Guyer J, Nuzum D (2007) Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 29:26–48

    Article  PubMed  CAS  Google Scholar 

  58. Bockbrader H, Burger P, Knapp L (2011) Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. Epilepsia 52:405–409

    PubMed  CAS  Google Scholar 

  59. Brodie M, Wilson E, Wesche D, Alvey C, Randinitis E, Posvar E, Hounslow N, Bron N, Gibson G, Bockbrader H (2005) Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 46:1407–1413

    Article  PubMed  CAS  Google Scholar 

  60. Bockbrader H, Wesche D, Miller R, Chapel S, Janiczek N, Burger P (2010) A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 49:661–669

    Article  PubMed  CAS  Google Scholar 

  61. McAuley D (2005) How does pregabalin compare to gabapentin in the treatment of neuropathic pain? Available at: http://www.globalrph.com/pregabalin.htm. Accessed 30 Aug 2012

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Maximilian Gahr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gahr, M., Freudenmann, R.W., Hiemke, C. et al. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol 69, 1335–1342 (2013). https://doi.org/10.1007/s00228-012-1464-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-012-1464-6

Keywords

Navigation